Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Sosei, Morphochem to Develop New Telomerase Inhibitor
April 2, 2001
- Industry FTC to Prohibit Financial Support for Social Gatherings at Medical Institutions
April 2, 2001
- Sankyo, Metabasis Agree to Continue Codevelopment of Antidiabetic Drug
April 2, 2001
- Sales of Relenza, Tamiflu Far Below Expectations
April 2, 2001
- Korosho to Start DRG Trial in April
April 2, 2001
- WORLD NEWS IN BRIEF
April 2, 2001
- Most municipal Hospitals Have Anti-Accident Manuals: JMHA Survey
April 2, 2001
- Major Japanese firms Aiming at 20% of Total Sales Overseas in 2005: JPMA Report
April 2, 2001
- MRSA Infections Found in 0.55% of Inpatients: Korosho Survey
April 2, 2001
- Final Draft of Ethical Guidelines for Human Genome Research Approved
April 2, 2001
- Sankyo Ties Up with Menarini to Market CS-866 in Europe
April 2, 2001
- 'Number System' Proposed for Social Security
April 2, 2001
- Celera to Acquire Minority Interest in HuBit Genomix
April 2, 2001
- Radicut, Herceptin, Zyvox Approved by CDFS
April 2, 2001
- DIAGNOSTIC NEWS IN BRIEF
April 2, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
April 2, 2001
- AIN PHARMACIEZ Issues Membership Cards
April 2, 2001
- 18.6% of Inpatients Can Be Discharged: Survey
April 2, 2001
- Sales of OTC Drugs in FY2000 Likely to Drop Due to Poor Prevalence of Flu
April 2, 2001
- Percentage of Deficit-ridden Hospitals Declines Slightly: NHFJ Survey
April 2, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…